These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 31278139)

  • 1. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
    McGonagle DG; McInnes IB; Kirkham BW; Sherlock J; Moots R
    Ann Rheum Dis; 2019 Sep; 78(9):1167-1178. PubMed ID: 31278139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
    Rosine N; Miceli-Richard C
    Front Immunol; 2020; 11():553742. PubMed ID: 33488572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
    Torgutalp M; Poddubnyy D
    Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports.
    Nagayasu A; Nawata M; Saito K; Tanaka Y
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):176-180. PubMed ID: 33086996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
    Braun J; Kiltz U; Baraliakos X
    Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies.
    Schwartzman S; Puig L; Cohen AD; Khattri S; Jossart C; Diaz C; Garrelts A; Ngantcha M; Eberhart N; Eleftheriadi A; Tangsirisap N; Schuster C; Gottlieb AB
    Expert Opin Drug Saf; 2024 Oct; 23(10):1347-1357. PubMed ID: 39234767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
    Manasson J; Wallach DS; Guggino G; Stapylton M; Badri MH; Solomon G; Reddy SM; Coras R; Aksenov AA; Jones DR; Girija PV; Neimann AL; Heguy A; Segal LN; Dorrestein PC; Bonneau R; Guma M; Ciccia F; Ubeda C; Clemente JC; Scher JU
    Arthritis Rheumatol; 2020 Apr; 72(4):645-657. PubMed ID: 31729183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
    Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
    Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis.
    Yousif P; Nahra V; Khan MA; Magrey M
    Joint Bone Spine; 2024 Jan; 91(1):105625. PubMed ID: 37495073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis.
    Harrison SR; Marzo-Ortega H
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1059-1071. PubMed ID: 34407705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
    Toussirot E
    Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current treatment for spondyloarthritis: focus on netakimab. A review].
    Karateev DE; Luchikhina EL
    Ter Arkh; 2024 Jun; 96(5):543-550. PubMed ID: 38829817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
    Braun J; Landewé RB
    Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
    Sánchez-Rodríguez G; Puig L
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
    Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
    Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?
    Siebert S; McGucken A; McInnes IB
    Curr Opin Rheumatol; 2020 Jul; 32(4):349-356. PubMed ID: 32412997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17A Interweaves the Skeletal and Immune Systems.
    Tang M; Lu L; Yu X
    Front Immunol; 2020; 11():625034. PubMed ID: 33613566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriatic arthritis and spondyloarthritis assessment and management update.
    Mease P
    Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis.
    Hammoura I; Fiechter RH; Bryant SH; Westmoreland S; Kingsbury G; Waegell W; Tas SW; Baeten DL; van de Sande MGH; van Tok MN; van Duivenvoorde LM
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.